A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder (MDD)

In brief

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Key facts

Study ID

NCT07300969

Run by

Draig Therapeutics Ltd

People needed

300

Starts

2025-12-16

Expected to finish

2027-08-01

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
• Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
• Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).

You may not qualify if…

• Pregnant or breastfeeding or plans to become pregnant during the study.
• Unstable medical condition or unstable chronic disease.
• Significant neurological abnormality.
• History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
• History of seizure.
• In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Where it is running

• Draig Clinical Site — Oxford, United Kingdom (enrolling)
• Draig Clinical Site — Little Rock, Arkansas, United States (enrolling)
• Draig Clinical Site — Oceanside, California, United States (enrolling)
• Draig Clinical Site — San Diego, California, United States (enrolling)
• Draig Clinical Site — Torrance, California, United States (enrolling)
• Draig Clinical Site — Miami, Florida, United States (enrolling)
• Draig Clinical Site — New Port Richey, Florida, United States (enrolling)
• Draig Clinical Site — Orlando, Florida, United States (enrolling)
• Draig Clinical Site — Atlanta, Georgia, United States (enrolling)
• Draig Clinical Site — Decatur, Georgia, United States (enrolling)
• Draig Clinical Site — Gaithersburg, Maryland, United States (enrolling)
• Draig Clinical Site — Watertown, Massachusetts, United States (enrolling)
• Draig Clinical Site — Flowood, Mississippi, United States (enrolling)
• Draig Clinical Site — Las Vegas, Nevada, United States (enrolling)
• Draig Clinical Site — Marlton, New Jersey, United States (enrolling)
• Draig Clinical Site — New York, New York, United States (enrolling)
• Draig Clinical Site — Media, Pennsylvania, United States (enrolling)
• Draig Clinical Site — Austin, Texas, United States (enrolling)
• Draig Clinical Site — Austin, Texas, United States (enrolling)
• Draig Clinical Site — DeSoto, Texas, United States (enrolling)
• Draig Clinical Site — Richardson, Texas, United States (enrolling)
• Draig Clinical Site — Wichita Falls, Texas, United States (enrolling)
• Draig Clinical Site — Bellevue, Washington, United States (enrolling)
• Draig Clinical Site — Říčany, Czechia (enrolling)
• Draig Clinical Site — Katowice, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.